ATE245697T1 - Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert - Google Patents

Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert

Info

Publication number
ATE245697T1
ATE245697T1 AT95107478T AT95107478T ATE245697T1 AT E245697 T1 ATE245697 T1 AT E245697T1 AT 95107478 T AT95107478 T AT 95107478T AT 95107478 T AT95107478 T AT 95107478T AT E245697 T1 ATE245697 T1 AT E245697T1
Authority
AT
Austria
Prior art keywords
bryodin
expression
cells
cloning
gene encoding
Prior art date
Application number
AT95107478T
Other languages
English (en)
Inventor
Clay B Siegall
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE245697T1 publication Critical patent/ATE245697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT95107478T 1994-05-17 1995-05-16 Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert ATE245697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/245,754 US5541110A (en) 1994-05-17 1994-05-17 Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica

Publications (1)

Publication Number Publication Date
ATE245697T1 true ATE245697T1 (de) 2003-08-15

Family

ID=22927947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95107478T ATE245697T1 (de) 1994-05-17 1995-05-16 Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert

Country Status (7)

Country Link
US (2) US5541110A (de)
EP (1) EP0710723B1 (de)
JP (1) JPH0898694A (de)
AT (1) ATE245697T1 (de)
CA (1) CA2148724A1 (de)
DE (1) DE69531332T2 (de)
ES (1) ES2203625T3 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541110A (en) * 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
IT1275909B1 (it) * 1995-03-07 1997-10-24 Mirella Pilone Frammento di dna codificante d-amminoacido ossidasi
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CN1152051C (zh) * 2000-08-02 2004-06-02 北京翔天牧生物科技有限公司 一种天花粉蛋白突变体及制备方法
EP1414838A4 (de) * 2001-07-19 2005-12-14 Yissum Res Dev Co Polypeptide mit carotenoidisomerasekatalytischer wirkung, nukleinsäuren, die für diese codieren, und deren verwendung
WO2003086273A2 (en) * 2002-04-08 2003-10-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone conjugates and uses thereof
US20060019885A1 (en) * 2002-06-11 2006-01-26 Matthew Baker Modified bryodin 1 with reduced immunogenicity
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
CN1767852B (zh) * 2003-01-31 2010-04-14 塞尔德克斯医疗公司 抗体疫苗缀合物及其用途
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20080057033A1 (en) * 2003-06-11 2008-03-06 Peter Lonai Neural Stem Cells and Methods of Generating and Utilizing Same
EP1751180A4 (de) * 2004-02-26 2012-01-04 Israel State Enzyme, zellen und verfahren zur stellenspezifischen rekombination an asymmetrischen stellen
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
WO2008120202A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
ES2445755T3 (es) * 2007-11-07 2014-03-05 Celldex Therapeutics, Inc. Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
EP2344179A1 (de) 2009-04-01 2011-07-20 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Verfahren zur steuerung der proliferation und differenzierung von keratinozyten
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
AU2011219426A1 (en) 2010-02-24 2012-10-04 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
US9267142B2 (en) 2010-03-08 2016-02-23 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011128895A2 (en) 2010-04-12 2011-10-20 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
WO2011138778A2 (en) 2010-05-04 2011-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
US20130164288A1 (en) 2010-09-07 2013-06-27 Protalix Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012046238A2 (en) 2010-10-06 2012-04-12 Ramot At Tel-Aviv University Ltd. Erythropoietin receptor antagonists
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
US9267129B2 (en) 2011-10-05 2016-02-23 Ben-Gurion University Of The Negev Research And Development Authority Compositions and methods for conferring herbicide resistance
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
EA201790960A3 (ru) 2012-02-14 2018-01-31 Опко Байолоджикс Лтд. Факторы свертывания крови пролонгированного действия и способы их получения
EP3401394A1 (de) 2012-02-22 2018-11-14 Exostem Biotec Ltd Erzeugung von neuralen stammzellen
EP3401393B1 (de) 2012-02-22 2020-02-19 Exostem Biotec Ltd Mikrornas zur erzeugung von astrocyten
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
EP2854838B1 (de) 2012-06-04 2018-10-17 OPKO Biologics Ltd. Pegylierte oxm-varianten
KR102202255B1 (ko) 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US10920192B2 (en) 2013-04-23 2021-02-16 Yeda Research And Development Co. Ltd. Isolated naive pluripotent stem cells and methods of generating same
CA2912997C (en) 2013-05-27 2021-09-07 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
WO2014195953A1 (en) 2013-06-05 2014-12-11 Ben Gurion University Of The Negev Research And Develpment Authority IL-1beta-IL-1Ra CHIMERA AND METHODS OF USING THE SAME
TW202317176A (zh) 2013-10-21 2023-05-01 以色列商歐科生物製品有限公司 長效型多肽及其生產和給藥的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
EP3240896A1 (de) 2015-01-04 2017-11-08 Protalix Ltd. Modifizierte dnase und verwendungen davon
EP3302571B1 (de) 2015-05-29 2020-11-18 OPKO Biologics Ltd. Pegylierte oxyntomodulin-varianten
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2017025963A1 (en) 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
IL241462A0 (en) 2015-09-10 2015-11-30 Yeda Res & Dev Heterologous engineering of betalain pigments in plants
EP3355911B1 (de) 2015-09-30 2022-11-02 Hadasit Medical Research Services And Development Limited Verwendung von volllängen-amelogenin zur förderung des nervenwachstums oder der nervenregeneration
CA3018305A1 (en) 2016-03-30 2017-10-05 Regentis Biomaterials Ltd. Treatments utilizing a polymer-protein conjugate
EP3468610A1 (de) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Langwirkende oxyntomodulinformulierung und verfahren zur herstellung und verabreichung davon
CN109689086A (zh) 2016-07-11 2019-04-26 国家生物技术研究所公司 具有延长的血清半衰期的融合蛋白
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
US11708421B2 (en) 2016-07-18 2023-07-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
IL247369B (en) 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
US11542508B2 (en) 2016-11-28 2023-01-03 Yeda Research And Development Co. Ltd. Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
CA3047707A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
IL250799A0 (en) 2017-02-26 2017-04-30 The Nat Inst For Biotechnology In The Negev Ltd Soluble chimeras of dr3 and pro-pilot ether and their use
WO2018229767A1 (en) 2017-06-13 2018-12-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for improving cell protein production yields
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited COMPOSITIONS AND METHODS FOR ENHANCING ALCOHOL TOLERANCE IN YEAST
WO2019043708A1 (en) 2017-08-30 2019-03-07 Hadasit Medical Research Services & Development Ltd. METHOD OF TREATMENT AND DIAGNOSIS OF METASTATIC LIVER CANCER
IL257269A (en) 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
BR112020020646A2 (pt) 2018-04-11 2021-02-23 Salubris Biotherapeutics, Inc. composições de proteína de fusão recombinante de neuregulina-1 (nrg-1) humana e métodos de uso destas
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
WO2021009740A1 (en) 2019-07-16 2021-01-21 Ramot At Tel-Aviv University Ltd. Compositions and methods for the treatment of tuberculosis
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
IL301970A (en) 2020-10-07 2023-06-01 Protalix Ltd A long-acting DNase
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for editing RNA and a method for using them
KR20230166078A (ko) 2021-02-05 2023-12-06 샐러브리스 바이오테라퓨틱스, 인크. Il-15 융합 단백질 및 이를 제조 및 사용하는 방법
WO2023012798A2 (en) 2021-08-02 2023-02-09 Yeda Research And Development Co. Ltd. Antibodies for the treatment of cancer
WO2023178086A1 (en) 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
WO2023209708A1 (en) 2022-04-25 2023-11-02 Yeda Research And Development Co. Ltd. Compositions for altering cyclic adp-ribose secondary messenger signalling

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513281A (en) 1982-04-05 1985-04-23 At&T Bell Laboratories AC plasma panel shift with intensity control
ES8504461A1 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
GB8619830D0 (en) * 1986-08-14 1986-09-24 Erba Farmitalia Inhibitor of protein synthesis
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IT1229216B (it) * 1989-03-31 1991-07-25 Italfarmaco Spa Proteine inibenti i ribosomi e loro derivati.
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
US5541110A (en) * 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica

Also Published As

Publication number Publication date
JPH0898694A (ja) 1996-04-16
DE69531332T2 (de) 2004-05-13
US5541110A (en) 1996-07-30
CA2148724A1 (en) 1995-11-18
EP0710723A1 (de) 1996-05-08
DE69531332D1 (de) 2003-08-28
US5932447A (en) 1999-08-03
ES2203625T3 (es) 2004-04-16
EP0710723B1 (de) 2003-07-23

Similar Documents

Publication Publication Date Title
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
IL150571A0 (en) Novel chimeric proteins and methods for using the same
IL128727A0 (en) Angiogenic factor and use thereof in treating cardiovascular disease
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
DE69434980D1 (de) Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend
GB9720054D0 (en) Biological products
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
JP2002535258A5 (de)
RU94034733A (ru) Способ получения клонирования и экспрессии гена, гены, иммунотоксины, продукты генов, днк, клетка, способ проверки гена и способ коррекции мутаций
DK1151102T3 (da) Glycosylerede leptinpræparater og relaterede fremgangsmåder
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
DE60042687D1 (de) Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen
ATE345139T1 (de) Karzinostatische wirkstoffe
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
DE69524971T2 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
ATE449173T1 (de) 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
DE60126602D1 (de) Neue collectine
GR3035006T3 (en) New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance.
ATE131175T1 (de) Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität.
Siegall Cloning and expression of a gene encoding bryodin 1 from bryonia dioica
DK0540560T3 (da) Ancrod-lignende proteiner, fremstilling og anvendelse deraf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties